Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: Miner who wrote (797)	12/15/2001 8:01:59 PM
From: Al Collard	Respond to of 4470

Hi Miner, Your in with DMX-t @$4.40 for 4,545 shares. Chart for Dimethaid Research, Inc: stockcharts.com[l,a]djcanimy[dc][pc20!b50!b100!b200!f][vc60][iUb14!Ll14!La12,26,9!Lh14,3!Lc20] From the chart of DMX we can see the stock has good support @$4.13 it's 50MA and resistance @$4.96 it's 100MA. The chart indicators are all bullish and pointing to further upside. I would expect this stock to test the resistance of it's 100MA shortly. Looks good Miner. Good luck with this pick, **** Al

To: Miner who wrote (797)	12/18/2001 7:47:23 AM
From: Al Collard	Respond to of 4470

DMX-t...in the news: Globe says FDA inspection excites Dimethaid investors Tue 18 Dec 2001 The Globe and Mail reports in its Tuesday, Dec. 18, edition that Dimethaid Research advanced for the second straight session following word that the United States Food & Drug Administration completed its inspection of the company's manufacturing plant for production of its lead product, Pennsaid. A Dow Jones Service dispatch to The Globe reports that Dimethaid posted the news last Thursday night on its Web site as part of an updated "president's message." While the FDA has yet to give the facility its stamp of approval, the company says it is "confident" that will soon follow. On Nov. 19, the stock spiked 39 per cent after a similar Web site update announced the the FDA inspection had been scheduled. Dimethaid stock rose 6 per cent or 26 cents to $4.66 on the Toronto Stock Exchange Monday. The stock has a 52-week trading range of $9.20 to $3.30.